Published in Free Radic Biol Med on January 01, 2003
A biochemical rationale for the discrete behavior of nitroxyl and nitric oxide in the cardiovascular system. Proc Natl Acad Sci U S A (2003) 1.78
Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: independence from beta-adrenergic signaling. Proc Natl Acad Sci U S A (2003) 1.76
Cardioprotection by metabolic shut-down and gradual wake-up. J Mol Cell Cardiol (2009) 1.68
Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling. Br J Pharmacol (2007) 1.52
The pharmacology of nitroxyl (HNO) and its therapeutic potential: not just the Janus face of NO. Pharmacol Ther (2006) 1.41
Retracted Nitroxyl (HNO): A Reduced Form of Nitric Oxide with Distinct Chemical, Pharmacological, and Therapeutic Properties. Oxid Med Cell Longev (2015) 1.40
The endogenous mitochondrial complex II inhibitor malonate regulates mitochondrial ATP-sensitive potassium channels: implications for ischemic preconditioning. Biochim Biophys Acta (2008) 1.33
The complex II inhibitor atpenin A5 protects against cardiac ischemia-reperfusion injury via activation of mitochondrial KATP channels. Basic Res Cardiol (2009) 1.28
Physiological and pharmacological features of the novel gasotransmitter: hydrogen sulfide. Biochim Biophys Acta (2009) 1.20
Redox regulation of the mitochondrial K(ATP) channel in cardioprotection. Biochim Biophys Acta (2010) 1.12
HNO and NO release from a primary amine-based diazeniumdiolate as a function of pH. Inorg Chem (2011) 1.10
Mechanisms of the interaction of nitroxyl with mitochondria. Biochem J (2004) 1.07
Playing with cardiac "redox switches": the "HNO way" to modulate cardiac function. Antioxid Redox Signal (2011) 1.07
The paradigm of postconditioning to protect the heart. J Cell Mol Med (2007) 1.07
The specificity of nitroxyl chemistry is unique among nitrogen oxides in biological systems. Antioxid Redox Signal (2011) 1.04
The role of gasotransmitters NO, H2S and CO in myocardial ischaemia/reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning. Br J Pharmacol (2014) 1.01
Physiological consequences of complex II inhibition for aging, disease, and the mKATP channel. Biochim Biophys Acta (2013) 0.99
Generation of nitroxyl by heme protein-mediated peroxidation of hydroxylamine but not N-hydroxy-L-arginine. Free Radic Biol Med (2008) 0.99
Catestatin reduces myocardial ischaemia/reperfusion injury: involvement of PI3K/Akt, PKCs, mitochondrial KATP channels and ROS signalling. Pflugers Arch (2013) 0.99
The emergence of nitroxyl (HNO) as a pharmacological agent. Biochim Biophys Acta (2009) 0.98
Catestatin improves post-ischemic left ventricular function and decreases ischemia/reperfusion injury in heart. Cell Mol Neurobiol (2010) 0.97
Early homing of adult mesenchymal stem cells in normal and infarcted isolated beating hearts. J Cell Mol Med (2008) 0.90
Identification of nitroxyl-induced modifications in human platelet proteins using a novel mass spectrometric detection method. Mol Cell Proteomics (2008) 0.89
Reactions of HNO with heme proteins: new routes to HNO-heme complexes and insight into physiological effects. Inorg Chem (2010) 0.88
Xerogel optical sensor films for quantitative detection of nitroxyl. Anal Chem (2008) 0.83
Post-ischemic early acidosis in cardiac postconditioning modifies the activity of antioxidant enzymes, reduces nitration, and favors protein S-nitrosylation. Pflugers Arch (2011) 0.82
Catestatin increases the expression of anti-apoptotic and pro-angiogenetic factors in the post-ischemic hypertrophied heart of SHR. PLoS One (2014) 0.82
Redox signalling and cardioprotection: translatability and mechanism. Br J Pharmacol (2015) 0.81
The shy Angeli and his elusive creature: the HNO route to vasodilation. Am J Physiol Heart Circ Physiol (2009) 0.81
Moving Forwards by Blocking Back-Flow: The Yin and Yang of MI Therapy. Circ Res (2016) 0.79
Discriminative EPR detection of NO and HNO by encapsulated nitronyl nitroxides. Free Radic Res (2012) 0.79
Quinone-enhanced reduction of nitric oxide by xanthine/xanthine oxidase. Chem Res Toxicol (2009) 0.78
Gene expression profiles of NO- and HNO-donor treated breast cancer cells: insights into tumor response and resistance pathways. Nitric Oxide (2014) 0.77
Glutathione sulfinamide serves as a selective, endogenous biomarker for nitroxyl after exposure to therapeutic levels of donors. Free Radic Biol Med (2014) 0.77
Biological signaling by small inorganic molecules. Coord Chem Rev (2016) 0.77
Nitroxyl inhibits overt pain-like behavior in mice: role of cGMP/PKG/ATP-sensitive potassium channel signaling pathway. Pharmacol Rep (2014) 0.76
Analysis of the HNO and NO donating properties of alicyclic amine diazeniumdiolates. Nitric Oxide (2014) 0.76
Chemotherapeutic potential of diazeniumdiolate-based aspirin prodrugs in breast cancer. Free Radic Biol Med (2015) 0.75
Synthesis and characterization of lithium oxonitrate (LiNO). J Inorg Biochem (2012) 0.75
The chemical biology of HNO signaling. Arch Biochem Biophys (2016) 0.75
pGlu-serpinin protects the normotensive and hypertensive heart from ischemic injury. J Endocrinol (2015) 0.75
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med (2004) 18.38
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med (2005) 6.50
Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol (2005) 5.39
Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation (2003) 4.51
Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc (2008) 4.50
Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science (2011) 4.36
Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ Res (2005) 3.93
Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation (2007) 3.78
Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function. Proc Natl Acad Sci U S A (2005) 3.64
Nitrite is a signaling molecule and regulator of gene expression in mammalian tissues. Nat Chem Biol (2005) 3.46
Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation (2005) 3.34
Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA (2003) 3.25
Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest (2005) 3.22
Local activation or implantation of cardiac progenitor cells rescues scarred infarcted myocardium improving cardiac function. Circ Res (2008) 3.07
Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation (2006) 3.01
Tackling heart failure in the twenty-first century. Nature (2008) 2.93
Systolic improvement and mechanical resynchronization does not require electrical synchrony in the dilated failing heart with left bundle-branch block. Circulation (2002) 2.88
The emerging biology of the nitrite anion. Nat Chem Biol (2005) 2.88
Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med (2003) 2.83
The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med (2008) 2.72
Optimal left ventricular endocardial pacing sites for cardiac resynchronization therapy in patients with ischemic cardiomyopathy. J Am Coll Cardiol (2010) 2.66
Cardiac magnetic resonance assessment of dyssynchrony and myocardial scar predicts function class improvement following cardiac resynchronization therapy. JACC Cardiovasc Imaging (2008) 2.64
Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations. Am J Physiol Regul Integr Comp Physiol (2004) 2.61
Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol (2006) 2.61
Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension (2006) 2.59
Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol (2005) 2.53
High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury. Circulation (2008) 2.47
Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation (2005) 2.38
PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Invest (2005) 2.36
Cellular targets and mechanisms of nitros(yl)ation: an insight into their nature and kinetics in vivo. Proc Natl Acad Sci U S A (2004) 2.33
Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circ Res (2005) 2.32
Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res (2012) 2.31
Nitrate and nitrite in biology, nutrition and therapeutics. Nat Chem Biol (2009) 2.29
The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest (2002) 2.26
Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci U S A (2005) 2.25
L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA (2006) 2.24
CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem (2006) 2.23
Retiming the failing heart: principles and current clinical status of cardiac resynchronization. J Am Coll Cardiol (2002) 2.22
Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ Res (2004) 2.19
Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci U S A (2005) 2.17
Increasing survival of ischemic tissue by targeting CD47. Circ Res (2007) 2.16
Nitrite as regulator of hypoxic signaling in mammalian physiology. Med Res Rev (2009) 2.15
Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models. Circ Res (2009) 2.11
Cardiac dyssynchrony analysis using circumferential versus longitudinal strain: implications for assessing cardiac resynchronization. Circulation (2005) 2.09
Electrophysiological consequences of dyssynchronous heart failure and its restoration by resynchronization therapy. Circulation (2009) 2.09
Post-conditioning induced cardioprotection requires signaling through a redox-sensitive mechanism, mitochondrial ATP-sensitive K+ channel and protein kinase C activation. Basic Res Cardiol (2006) 2.08
Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol (2007) 2.07
Cardiac resynchronization therapy: Part 1--issues before device implantation. J Am Coll Cardiol (2005) 2.06
Impact of arterial load and loading sequence on left ventricular tissue velocities in humans. J Am Coll Cardiol (2007) 2.05
Multiple reaction monitoring to identify site-specific troponin I phosphorylated residues in the failing human heart. Circulation (2012) 2.05
Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A (2002) 2.04
Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens (2007) 2.01
Cardiac resynchronization therapy: Part 2--issues during and after device implantation and unresolved questions. J Am Coll Cardiol (2005) 1.98
Functional impact of rate irregularity in patients with heart failure and atrial fibrillation receiving cardiac resynchronization therapy. Eur Heart J (2004) 1.95
Dynamic changes in conduction velocity and gap junction properties during development of pacing-induced heart failure. Am J Physiol Heart Circ Physiol (2007) 1.94
Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload. J Clin Invest (2011) 1.94
Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation (2011) 1.92
Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res (2005) 1.91
Plasma nitroso compounds are decreased in patients with endothelial dysfunction. J Am Coll Cardiol (2006) 1.91
Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci U S A (2004) 1.87
Ventricular-arterial coupling, remodeling, and prognosis in chronic heart failure. J Am Coll Cardiol (2013) 1.86
Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans. Free Radic Biol Med (2005) 1.85
Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov (2007) 1.83
Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation (2008) 1.82
Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest (2009) 1.79
A biochemical rationale for the discrete behavior of nitroxyl and nitric oxide in the cardiovascular system. Proc Natl Acad Sci U S A (2003) 1.78
Brief periods of nitric oxide inhalation protect against myocardial ischemia-reperfusion injury. Anesthesiology (2008) 1.77
Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol (2009) 1.77
Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: independence from beta-adrenergic signaling. Proc Natl Acad Sci U S A (2003) 1.76
Cardioprotective effects of thioredoxin in myocardial ischemia and reperfusion: role of S-nitrosation [corrected]. Proc Natl Acad Sci U S A (2004) 1.76
Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling. Blood (2007) 1.73
cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res (2004) 1.73
Cardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal nitric oxide synthase. J Am Coll Cardiol (2012) 1.72
Concomitant presence of N-nitroso and S-nitroso proteins in human plasma. Free Radic Biol Med (2002) 1.71
Hyperactive adverse mechanical stress responses in dystrophic heart are coupled to transient receptor potential canonical 6 and blocked by cGMP-protein kinase G modulation. Circ Res (2014) 1.70
Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res (2002) 1.70
Tetrahydrobiopterin and cardiovascular disease. Arterioscler Thromb Vasc Biol (2006) 1.68
Oxidation and nitrosation of thiols at low micromolar exposure to nitric oxide. Evidence for a free radical mechanism. J Biol Chem (2003) 1.68
Diastolic dysfunction is associated with myocardial viral load in simian immunodeficiency virus-infected macaques. AIDS (2012) 1.68
Reversal of global apoptosis and regional stress kinase activation by cardiac resynchronization. Circulation (2008) 1.67
Ventricular-vascular interaction in heart failure. Heart Fail Clin (2008) 1.67
Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther (2009) 1.66
Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. J Am Coll Cardiol (2010) 1.65